.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Teva
US Department of Justice
Daiichi Sankyo
Medtronic
Julphar
QuintilesIMS
Mallinckrodt
AstraZeneca
Healthtrust
Baxter

Generated: September 20, 2017

DrugPatentWatch Database Preview

Nps Pharms Inc Company Profile

« Back to Dashboard

What is the competitive landscape for NPS PHARMS INC, and what generic alternatives to NPS PHARMS INC drugs are available?

NPS PHARMS INC has one approved drug.

There are eleven US patents protecting NPS PHARMS INC drugs.

There are seventy-five patent family members on NPS PHARMS INC drugs in eighteen countries.

Summary for Applicant: Nps Pharms Inc

Patents:11
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Nps Pharms Inc
GATTEX KIT
teduglutide recombinant
POWDER;SUBCUTANEOUS203441-001Dec 21, 2012RXYesYes► Subscribe► Subscribe► Subscribe
Nps Pharms Inc
GATTEX KIT
teduglutide recombinant
POWDER;SUBCUTANEOUS203441-001Dec 21, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Nps Pharms Inc
GATTEX KIT
teduglutide recombinant
POWDER;SUBCUTANEOUS203441-001Dec 21, 2012RXYesYes► Subscribe► SubscribeY ► Subscribe
Nps Pharms Inc
GATTEX KIT
teduglutide recombinant
POWDER;SUBCUTANEOUS203441-001Dec 21, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Nps Pharms Inc
GATTEX KIT
teduglutide recombinant
POWDER;SUBCUTANEOUS203441-001Dec 21, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Nps Pharms Inc
GATTEX KIT
teduglutide recombinant
POWDER;SUBCUTANEOUS203441-001Dec 21, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Nps Pharms Inc
GATTEX KIT
teduglutide recombinant
POWDER;SUBCUTANEOUS203441-001Dec 21, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Nps Pharms Inc
GATTEX KIT
teduglutide recombinant
POWDER;SUBCUTANEOUS203441-001Dec 21, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Nps Pharms Inc
GATTEX KIT
teduglutide recombinant
POWDER;SUBCUTANEOUS203441-001Dec 21, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
Nps Pharms Inc
GATTEX KIT
teduglutide recombinant
POWDER;SUBCUTANEOUS203441-001Dec 21, 2012RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Nps Pharms Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,834,428 Glucagon-like peptide-2 and its therapeutic use► Subscribe
7,781,401Glucagon-like peptide-2 analogs► Subscribe
7,049,284Glucagon-like peptide-2 and its therapeutic use► Subscribe
6,184,201 Intestinotrophic glucagon-like peptide-2 analogs► Subscribe
8,933,039Glucagon-like peptide-2 analogs► Subscribe
5,990,077 Glucagon-like peptide-2 and its therapeutic use► Subscribe
8,846,625Glucagon-like peptide-2 analogs► Subscribe
7,888,317Glucagon-like peptide-2 and its therapeutic use► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Nps Pharms Inc Drugs

Country Document Number Estimated Expiration
Japan2014159463► Subscribe
Japan5197012► Subscribe
Denmark1809318► Subscribe
Canada2251576► Subscribe
Denmark1246639► Subscribe
Hong Kong1050204► Subscribe
Portugal1231219► Subscribe
Hong Kong1050142► Subscribe
United Kingdom9930882► Subscribe
European Patent Office1231219► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Nps Pharms Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90009-7Sweden► SubscribePRODUCT NAME: TEDUGLUTID; REG. NO/DATE: EU/1/12/787/001 20120830
2013 00012Denmark► Subscribe
C0013France► SubscribePRODUCT NAME: TEDUGLUTIDE; REGISTRATION NO/DATE: EU/1/12/787/001 20120830
153Luxembourg► SubscribePRODUCT NAME: TEDUGLUTIDE SOUS TOUTES SES FORMES, TELLES QU ELLES SONT PROTEGEES PAR LE BREVET DE BASE
13/006Ireland► SubscribePRODUCT NAME: TEDUGLUTIDE; REGISTRATION NO/DATE: EU/1/12/787/001 20120830
3Finland► Subscribe
00578Netherlands► SubscribePRODUCT NAME: TEDUGLUTIDE OR A PHARMACEUTICALLY ACCEPTABLE FORM THEREOF; REGISTRATION NO/DATE: EU/1/12/787/001 20120830
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
US Army
Healthtrust
Farmers Insurance
Fuji
Fish and Richardson
Deloitte
Colorcon
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot